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Aims Depression and anxiety are linked to coronary events but the mechanism(s) remains unclear. We investigated the
associations of depression and anxiety with serotonin-mediated platelet hyperactivity in coronary artery disease
(CAD) patients in a cross-sectional study.
Methods
and results
Three months after an acute coronary event, stable CAD patients (n ¼ 83) on aspirin and clopidogrel were evaluated
for depression (beck depression inventory) and anxiety (hospital anxiety and depression scale), and their platelet
reactivity was measured (optical aggregometry and flow cytometric fibrinogen binding in response to adenosine
diphosphate (ADP ¼ 5 mM) and two serotonin þ epinephrine doses [5HT:E (L) ¼ 4 mM þ 4 mM and 5HT:E
(H) ¼ 10 mM þ 4 mM]. Platelet reactivity was significantly higher in depressed and anxious than in depressed only or
non-depressed-and-non-anxious patients. Aggregation (mean+ SE) was 41.9+2.6% vs. 32.2+2.6% vs. 30.4+ 3.7%
with 5HT:E (L) and 46.9+ 2.7% vs. 35.6+2.7% vs. 31.7+3.8% with 5HT:E (H) (P, 0.05 for both). Differences
in ADP aggregations were not significant, perhaps because of clopidogrel therapy. Flow cytometry findings were
similar. In a multivariate linear regression model adjusted for age, body mass index, and each other, anxiety symptoms
independently predicted all 5HT:E-mediated platelet reactivity measures, whereas depression predicted none.
Conclusion Anxiety is associated with elevated serotonin-mediated platelet reactivity in stable CAD patients and symptoms of
anxiety show strong, independent correlations with platelet function.
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Introduction
Coronary artery disease (CAD) and its thrombotic manifestations
remain the leading cause of morbidity and mortality in the industri-
alized nations. The importance of psychosocial factors as contribu-
tors to the incidence and progression of CAD has been the focus
of a concerted research effort over the years.1 –8 For example, the
INTERHEART study,9 a case–control examination of modifiable
risk factors in 52 countries, found that a composite variable com-
prises exposure to depression, perceived life stress, low control,
and major life events carried an adjusted 2.67-fold increased risk
of acute myocardial infarction (AMI). Indeed, the contribution of
depression and anxiety to increased likelihood of recurrent coron-
ary events after AMI and bypass surgeries,2,10–13 and transient
depressed and anxious mood as trigger acute cardiac events and
potentially fatal arrhythmias is well documented.14– 16 The risk
associated with depression in these populations, where its preva-
lence can be up to 10 times greater than in the healthy
groups,17,18 is comparable to that of smoking, hypertension or dia-
betes, and independent of such traditional cardiovascular risk
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factors such as left ventricular ejection fraction, history of myocar-
dial infarction or Killip class.19– 22 On the basis of this literature, an
American Heart Association science advisory has recommended
screening for depression in CAD patients.23
Anxiety is also highly prevalent in cardiac populations, with esti-
mates ranging from 28 to 44% in younger groups and from 14 to
24% in older groups.24,25 Furthermore, anxiety is a frequently encoun-
tered co-morbidity of depression.26 Though the aetiologies, mechan-
isms, and sequelae of anxiety and depression share many
commonalities,27,28 there are many distinctions as well.29 The impact
of depression on cardiac events has been extensively investigated.19
The few studies that have evaluated the prognostic value and individual
contribution of depression and/or anxiety towards CAD outcomes
show that when evaluated concurrently, anxiety frequently carries
the cardiac risk alone,30–33 although this observation is not universal.34
Increased platelet reactivity is one of several mechanisms postu-
lated in explaining the link between psychosocial factors and
CAD.35–37 A recent review by Bruce and Musselman38 found con-
siderable evidence linking depression to increased platelet acti-
vation in both groups with extant CAD and those with only
CAD risk factors. Others have found greater platelet responsive-
ness and prolonged platelet activation among individuals character-
ized by hostility and chronic psychological stress.39– 41 Acute
psychological stress can similarly affect platelet function,42 particu-
larly among those prone to anxiety.43
Platelets are activated by their interaction with various circulating
agonists (including serotonin and catecholamines) via separate and
specific receptors in the platelet membrane. Serotonin (5HT) is con-
sidered an important element in psychopathology and psychophar-
macology and specific 5HT2A receptors have been reported to
play a role in platelet aggregation.44 A higher 5HT-mediated platelet
reactivity has been described in depressed patients compared with
healthy, non-depressed adults.45 Alternatively, catecholamines acti-
vate platelets via stimulation of platelets’ a-2 receptors.46,47 As the
two agonists act through different pathways, a synergistic effect
between 5HT and epinephrine on platelets has been observed;48
levels of autonomic activity and circulating catecholamines are elev-
ated in patients with anxiety,49 which could lead to the activation of
platelets in these patients. Given the link of depression and anxiety
with increased risk of cardiovascular events, we investigated their
associations with platelet reactivity in patients with stable CAD.
Methods
Study population and design
The study was conducted using a cross-sectional design on CAD
patients admitted to the Mount Sinai Medical Center in New York
for acute coronary syndrome (ACS), including AMI and unstable
angina from April 2005 to March 2008. Patients were recruited (n ¼
83) during their first week of admission for ACS and scheduled for
follow-up visit 3 months later to allow any post-ACS changes in plate-
let function to subside and for the platelet reactivity to stabilize. During
3-month follow-up visit, patients were assessed for symptoms of
depression and anxiety, and their platelet reactivity was measured by
investigators blinded to the results of these assessments (Figure 1).
All subjects were on daily aspirin (81 mg) and clopidogrel (75 mg)
therapy at the time of platelet testing.
The study complies with the Declaration of Helsinki and was
approved by the Institutional Review Board of Mount Sinai Medical
Center. A written informed consent was obtained from each patient
before initiating any study-related procedures.
Inclusion criteria
Patients 18 years and older were eligible if they had been hospitalized
for an ACS event—either AMI with or without ST-elevation or
unstable angina.
Exclusion criteria
Active suicidal or homicidal ideation (these patients require and were
provided immediate referral for further evaluation); antidepressant
treatment within 6 weeks prior to study enrolment; current alcohol
or other substance abuse disorders; any current psychotic disorder;
history of psychotic, bipolar or serious personality disorders; diagnosis
of a terminal non-cardiac illness; inability to communicate in English or
Spanish; levels of cognitive impairment indicative of dementia.
Assessment of depression and anxiety
symptom severity
Patients completed the beck depression inventory (BDI)50 and the
anxiety subscale of the hospital anxiety and depression scale
(HADS-A),51 each of which measure symptom severity. These scales
are commonly used in research and clinical practice, and scores have
been linked to post-ACS prognosis in prior research.34
For categorical analysis, patients were classified as depressed if they
had a BDI score of 10. Although this threshold is not specific for
major depression, it is clinically meaningful, and prior research has
found this threshold to carry increased risk for post-ACS recurrent
cardiac events.19 Patients were similarly classified as anxious, if they
had a HADS-A score of 8, using previously published cutoffs for
identifying individuals with clinically meaningful levels of anxiety.52,53
This classification yielded four groups: (i) non-depressed and non-anxious,
(ii) depressed only, (iii) anxious only, and (iv) depressed and anxious.
Blood sampling
Platelet reactivity was measured during the office visit scheduled 3 months
after the ACSevent. Steps were taken tostandardizeblood collectionpro-
cedures as much as possible, including scheduling the blood sampling
around the same time of day (early afternoon) and collecting the blood
after the interview, allowing physical rest time for the patient before the
blood draw. In order to minimize unintended platelet activation, tourni-
quet pressure was kept to a minimum during the 19-gauge butterfly
stick and the initial 3 mL of blood was discarded. Samples were then col-
lected in 3.2% sodium citrate tubes that were gently inverted 3–5 times
and kept in upright position till processing. Tests for the measurement
of platelet reactivity were initiated within 2 h of blood collection.
Platelet reactivity
Two different techniques were employed for the measurement of platelet
reactivity: optical aggregometry and flow cytometry. In both method-
ologies, platelets were activated using three agonists: (i) adenosine dipho-
sphate (ADP 5 mM), (ii) 5HT:E (L) (serotonin 4 mM with epinephrine
4 mM), and (iii) 5HT:E (H) (serotonin 10 mM with epinephrine 4 mM).
As serotonin alone is a weak agonist of platelets, a fixed concentration of
epinephrine was added to both of its doses to amplify its stimulatory effect.
† Platelet aggregation studies were conducted in platelet-rich plasma
using optical aggregometry as previously described.54 The aggreg-
ometer (Model 570VS) and reagents for platelet aggregation were
purchased from Chrono-log, Havertown, PA, USA.
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† Platelet surface receptor activation studies were carried out in
whole blood by measuring fibrinogen binding to the glycoprotein
IIb/IIIa receptor complex on platelet surface, following activation
with ADP and 5HT:E.54 Blood sample was split into 200 mL aliquots,
and incubated with the agonists for 10 min, followed by 30 min of
direct immunofluorescence staining. Phycoerythrin-conjugated
CD42b antibody (Immunotech, Fullerton, CA, USA) was used to
label all platelets and the activated sub-population was identified
using the anti-human fibrinogen antibody conjugated with fluor-
escein isothiocyanate (WAK-Chemie Medical GmbH, Steinbach,
Germany). Samples were fixed with 2% paraformaldehyde and ana-
lysed in BD FACSCaliburTM using CellQuest Pro software (BD Bio-
sciences, San Jose, CA, USA) without delay.
Statistical analysis
The data were analysed using SPSS (version 16) and SYSTAT (version
10) statistical software. Data are summarized as means+ standard
deviations (unless specified otherwise) or percentages for frequency
data. Statistical significance was set at the nominal P, 0.05 level and
no adjustments were made for multiple comparisons. Standard univari-
ate plots (e.g. stem and leaf, boxplots) and bivariate plots (e.g. residual-
predictor, quantile–quantile) were used to assess distributional and
other assumptions of the analyses. We did not find any clear depar-
tures from these assumptions in these data.
Simple correlations were used to summarize the basic relation of
anxiety and depression symptom severity with platelet aggregation,
and multiple regression was used to evaluate the partial relation of
these two factors to platelet aggregation measures, adjusting for the
covariates and each other. Covariates were selected judiciously
based on consistent significant correlations between the covariates
and the independent or dependent variables. For the categorical ana-
lyses, anxiety and depression were dummy coded using the standard
cutoffs described previously, as 0 ¼ below the cutoff and 1 ¼ at or
above the cutoff. The covariates were centred around their sample
mean as were the BDI and HADS-A scores for the continuous analysis.
The predicted aggregation measures were adjusted at the means of the
covariates. The sample size for this study is relatively small, but with
this sample size we had power of 0.80 to detect moderate simple cor-
relations and for the regression analysis we had power of 0.80 to
detect a large population partial correlation.
The authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the manuscript as
written.
Results
Demographic characteristics of the total study population and its
grouping according to depression and anxiety status are presented
Figure 1 Flow chart of the study design. MSMC, Mount Sinai Medical Center; ACS, acute coronary syndrome.
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in Table 1. Only two patients qualified for the category of anxious
only and their data, although included in analyses, are not pre-
sented except in Table 1. The reporting has been structured fol-
lowing the STROBE statement guidelines.55
There were no statistically significant differences, based on
one-way ANOVAs or 2  3 contingency table analyses between
the groups except in their BDI and HADS-A scores, which was
expected. Overall, a moderate correlation was observed
between scores on these indices of depression and anxiety
symptom severity (r2 ¼ 0.51, P, 0.001).
Figures 2 and 3 (top panels) present the mean platelet reactiv-
ity of patients after adjusting for age and body mass index (BMI).
For the two anxiety only patients, the means (+standard errors)
of platelet aggregation (ADP—17.1+ 10.1%, 5HT:E (L)—43.4+
10.3%, and 5HT:E (H)—49.0+ 10.6%) and platelet surface
receptor activation (ADP—13.3+ 13.4%, 5HT:E (L)—23.5+
12.7%, and 5HT:E (H)—25.5%+ 12.5%) are not included in the
figures.
The anxiety only groups (with and without depression) demon-
strated a consistent association with higher reactivity to serotonin,
in all measures of platelet function. In aggregation studies, the
depressed and anxious group had significantly higher 5HT:E-
mediated platelet reactivity than the depressed only and the non-
depressed and non-anxious groups, whereas the latter two groups
were not significantly different from each other (Figure 2). Platelet
aggregation in response to ADP was higher in the depressed
groups (with and without anxiety) vs. the non-depressed, but
this was not statistically significant.
Findings in the flow cytometric assessment of platelet activation
were similar (Figure 3), but only the results with high-dose 5HT:E
achieved statistical significance.
Depression and anxiety symptom severity
as predictors of platelet reactivity
Anxiety symptom severity, represented by continuous HADS-A
scores, exhibited consistent correlations with serotonin-mediated
platelet reactivity in both aggregation and flow cytometry
studies. These correlations were significant with 5-HT:E-mediated
aggregations at both low dose (r ¼ 0.25, P ¼ 0.023) and high
dose (r ¼ 0.28, P ¼ 0.011). In flow cytometry studies, these
correlations were just as strong with platelet surface receptor
activation in response to 5HT:E (r ¼ 0.33, P ¼ 0.003 with low
dose and r ¼ 0.28, P ¼ 0.012 with high dose). Depression
symptom severity displayed a weaker and inconsistent relation-
ship to platelet reactivity measures, with some degree of corre-
lation noted in 5HT:E-mediated aggregation that only reached
statistical significance with the high dose (r ¼ 0.20, P ¼ 0.079
and r ¼ 0.26, P ¼ 0.02). Neither depression nor anxiety
symptom severity showed any associations with ADP-mediated
platelet reactivity.
To better define the relationship of depression and anxiety
symptom severity with platelet reactivity, a multivariate model
was tested, controlling for age and BMI. With both BDI and
HADS-A score in the equation, anxiety symptom severity
remained a significant predictor of 5HT-mediated platelet reactiv-
ity, whereas depression symptom severity did not (Tables 2 and 3,
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Age (years) 61.9+11.1 61.9+13.8 65.0+9.8 59.7+10.4 0.15 50.0+1.4
Males (%) 41 (49.4) 12 (70.6) 13 (40.6) 14 (43.8) 0.11 2 (100.0)
Body mass index (kg/m2) 29.7+5.7 26.8+5.2 30.7+7.5 30.7+4.9 0.08 27.9+1.8
Diabetes (%) 38 (45.8) 7 (43.8) 15 (46.9) 16 (50.0) 0.92 0 (0.0)
Current smoker (%) 22 (26.5) 3 (17.6) 10 (31.3) 8 (25.0) 0.58 1 (50.0)
Hypertension (%) 70 (84.3) 15 (88.2) 28 (87.5) 27 (84.4) 0.91 0 (0.0)
Hypercholesterolaemia
(%)
61 (73.5) 11 (64.7) 21 (67.7) 28 (87.5) 0.11 1 (50.0)
Previous MI (%) 20 (24.7) 1 (5.9) 10 (31.2) 9 (28.1) 0.12 0 (0.0)
Systolic BP (mmHg) 129.3+20.2 124.9+19.6 134.9+20.8 127.4+20.0 0.21 114.5+13.4
Diastolic BP (mmHg) 74.4+11.4 76.2+7.8 71.8+10.8 75.3+13.5 0.35 77.5+3.5
Total cholesterol (mg/dL) 155.3+45.4 157.9+43.5 145.5+41.1 163.7+51.1 0.97 165.5+0.7
LDL (mg/dL) 87.4+37.1 95.5+39.6 82.0+33.5 89.4+40.5 0.48 74.5+13.4
HDL (mg/dL) 45.6+12.5 42.4+8.7 48.2+13.7 44.8+11.2 0.12 52.5+36.1
Triglycerides (mg/dL) 113.1+80.8 116.5+96.7 83.6+42.1 134.5+92.1 0.58 192.0+107.5
Beta-blockers (%) 60 (72.3) 11 (64.7) 25 (78.1) 23 (71.9) 0.60 1 (50.0)
Lipid-lowering meds. (%) 69 (83.1) 15 (88.2) 24 (75.0) 28 (87.5) 0.33 2 (100.0)
ACE-inhibitors (%) 35 (42.2) 6 (35.3) 15 (46.9) 14 (45.2) 0.72 0 (0.0)
ARBs (%) 16 (19.8) 2 (11.8) 5 (15.6) 9 (28.1) 0.30 0 (0.0)
Ca-channel blockers (%) 23 (27.7) 3 (17.6) 11 (34.4) 9 (28.1) 0.47 0 (0.0)
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; Ca, calcium; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction.
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bottom panels of Figures 2 and 3). Thus, depression symptom
severity, which had exhibited significant correlation with high-dose
5HT:E platelet aggregation in the unadjusted analysis, was no
longer associated with any of the platelet reactivity measures. Find-
ings with ADP-mediated platelet reactivity did not change from the
unadjusted analysis.
To ensure that the differences in platelet reactivity to 5HT:E
were in fact serotonin-mediated and not the result of epinephrine,
same concentration of epinephrine (4 mM) was tested separately
as a sole platelet aggregation agonist. No differences in
epinephrine-mediated platelet reactivity between any of the
groups were observed (data not shown).
Discussion
Despite the associations of psychological factors with recurrent
cardiac events, and emerging evidence that in addition to such
factors as hostility and depression, anxiety may have independent
‘cardiotoxic’ effects, few studies have examined the roles of
depression and anxiety in such associations concurrently. Further-
more, a complete understanding of the mechanisms that may link
these emotional factors with cardiac events has been lacking.13
Depression has been associated with an increase in platelet reac-
tivity in ACS patients, and serotonin, one of many platelet activa-
tors, has been hypothesized to be one of the links connecting
Figure 2 Top panel shows platelet aggregation result (estimated means+ standard error) in stable CAD patients grouped into non-depressed
and non-anxious (Dep2 Anx2), depressed only (Depþ Anx2), and depressed and anxious (Depþ Anxþ). Bottom panel presents linear relations
of depressive and anxious symptoms (BDI and HADS-A scores expressed in standard deviations from their means) to aggregation after con-
trolling for age, BMI, and each other. *P, 0.05.
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the two variables. Anxiety has similarly been associated with plate-
let function and activity during laboratory stress probes among
individuals characterized by chronic life stress.40
Our aim was to investigate the associations of both depression and
of anxiety with platelet function among patients several months after
ACS when they were presumed to be stable. We also sought to
assess the independent predictive value of these factors on platelet
function in the same model. We found that patients categorized
with depression demonstrated greater platelet reactivity to both
ADP and serotonin, though this relationship did not reach statistical
significance. In contrast, patients characterized with anxiety, accord-
ing to this same criterion, demonstrated significantly greater platelet
reactivity. A multivariate model that included these two factors as
continuous measures of symptom severity revealed that only
anxiety was associated with higher platelet reactivity, in both aggrega-
tion and flow cytometric measures of platelet function, and further-
more, that this hyper-reactivity was mediated via serotonin. The
lack of any significant differences in the ADP-mediated platelet reac-
tivity could be due to clopidogrel treatment, which specifically inhibits
the P2Y12 receptor responsible for ADP-mediated platelet reactivity.
Aspirin and clopidogrel combination therapy has also been reported
to affect serotonin-induced platelet aggregation at 15 min, but not
6 min, of test run.56 However, as our run times for aggregation
studies were 6 min and all patients were on daily aspirin (81 mg)
and clopidogrel (75 mg) therapy for 3 months prior to platelet
function testing, it is unlikely to be a factor of any significance.
Figure 3 Top panel presents flow cytometric measurement of platelet surface receptor activation (estimated means+ standard error) in
stable CAD patients grouped into non-depressed and non-anxious (Dep2 Anx2), depressed only (Depþ Anx2), and depressed and anxious
(Depþ Anxþ). Bottom panel presents linear relations of depressive and anxious symptoms (BDI and HADS-A scores expressed in standard
deviations from their means) to platelet surface receptor activation after controlling for age, BMI, and each other. *P, 0.05.
M.U. Zafar et al.1578
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Table 2 Relation of depression and anxiety symptom severity to platelet aggregation
Unstandardized coefficients Standardized coefficients t P-value
Beta Std. error Beta
ADP-mediated
Constant 25.48 1.56 16.30 0.00
Depressive symptoms 0.48 0.25 0.25 1.95 0.06
Anxious symptoms 20.19 0.43 20.06 20.45 0.65
Age 0.22 0.15 0.17 1.50 0.14
BMI 20.44 0.28 20.17 21.58 0.12
5HT:E (low dose)-mediated
Constant 35.90 1.59 22.63 0.00
Depressive symptoms 0.13 0.25 0.07 0.54 0.59
Anxious symptoms 0.99 0.43 0.29 2.28 0.03
Age 0.27 0.15 0.20 1.87 0.07
BMI 20.61 0.26 20.25 22.35 0.02
5HT:E (high dose)-mediated
Constant 39.59 1.64 24.13 0.00
Depressive symptoms 0.25 0.26 0.12 0.98 0.33
Anxious symptoms 1.12 0.45 0.30 2.49 0.02
Age 0.40 0.15 0.28 2.64 0.01
BMI 20.62 0.27 20.24 22.30 0.02
ADP, adenosine diphosphate; BMI, body mass index; 5HT:E, serotonin þ epinephrine. Bold values indicate P , 0.05.
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Table 3 Relation of depression and anxiety symptom severity to platelet receptor activation
Unstandardized coefficients Standardized coefficients t P-value
Beta Std. error Beta
ADP-mediated
Constant 31.99 1.52 21.03 0.00
Depressive symptoms 20.08 0.24 20.04 20.33 0.75
Anxious symptoms 0.49 0.41 0.16 1.20 0.24
Age 0.25 0.14 0.21 1.81 0.08
BMI 20.37 0.28 20.15 21.32 0.19
5HT:E (low dose)-mediated
Constant 24.40 1.32 18.44 0.00
Depressive symptoms 20.28 0.21 20.16 21.32 0.19
Anxious symptoms 1.37 0.36 0.48 3.83 <0.01
Age 0.35 0.12 0.31 2.88 <0.01
BMI 20.09 0.22 20.04 20.38 0.71
5HT:E (high dose)-mediated
Constant 24.81 1.38 17.94 0.00
Depressive symptoms 20.28 0.22 20.16 21.28 0.21
Anxious symptoms 1.30 0.37 0.44 3.47 <0.01
Age 0.42 0.13 0.35 3.31 <0.01
BMI 20.06 0.23 20.03 20.25 0.81
ADP, adenosine diphosphate; BMI, body mass index; 5HT:E, serotonin þ epinephrine. Bold values indicate P , 0.05.
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Our findings suggest that although depression is associated with
general platelet hyper-reactivity, anxiety may be a more dominant
factor driving this increase, mediated via serotonin. This biological
mechanism may account for the increased risk of recurrent events
observed in cardiac patients with clinically meaningful levels of
anxiety. The association of anxiety with platelet reactivity could
also provide a plausible explanation for some of the inconsistencies
in published reports linking emotional distress with increased CVD
risk.57 A varying proportion of patients with anxiety may be
enrolled in some of these studies, rendering anxiety an unmea-
sured confound.
Our present study supports the findings reported in recent clini-
cal studies. For example, Strik et al.32 reported both anxiety and
depression to be predictors of cardiac death or recurrent events
in post-AMI patients, whereas Frasure-Smith and Lesperance34
found both depression and anxiety to be predictive of cardiac
events in stable post-ACS patients. However, in both studies,
multivariate analysis including both depression and anxiety
showed only anxiety to be an independent predictor of recurrent
events. In yet another study, average exposure to anxiety over time
in stable CAD patients was independently associated with an
increased risk of non-fatal myocardial infarction or mortality; this
study, however, did not examine the contributions of depression.58
It is important to note that a number of pathways have been
suggested to link psychological factors, including depression and
anxiety, to CAD-related outcomes. Among these are dysregulation
in autonomic function, characterized by increased sympathetic and
decreased parasympathetic control59 and inflammatory pro-
cesses.60,61 Furthermore, the influence of autonomic pathways in
the regulation of inflammatory processes, as suggested by
Tracey,62 has been observed in depressed patients with CHD.63
Of interest, the latter study also found indices of coagulability elev-
ated in relation to autonomic factors in this population; whether
this occurs when anxiety is present is not yet known.
Current guidelines suggest screening cardiac patients for
depression as its presence signals a worse cardiovascular progno-
sis.23 Much less attention has been focused on anxiety. Our find-
ings suggest that we should also be alert to symptoms of anxiety
in these patients. Their timely identification could lead to the
initiation of appropriate intervention to mitigate the risk for
adverse cardiovascular outcomes associated with this factor. Inter-
ventions to accomplish this could include both more intensive anti-
platelet therapy to directly address the mechanisms revealed in the
current study, and behavioural interventions including exercise
training that has also been shown to reduce depression and
improve event free-survival in CAD patients,25,64 and stress man-
agement, which has been shown to reduce overall psychosocial
risk while improving both event-free survival and emotional
stress provoked myocardial ischaemia.65 However, it remains
unknown if decreasing anxiety would remediate platelet function,
or improve CAD outcomes.
Study limitations
The overall study sample was small and thus, the number of
patients who qualified as anxious but not depressed in this study
was low. This, however, represents the real world occurrence of
anxiety, which is rarely encountered in the absence of depression.
Importantly, this limitation applies only to the categorical analyses
and is overridden by the stronger findings of the multivariate analy-
sis, where symptoms of anxiety are shown to have a highly signifi-
cant, linear relationship with platelet reactivity, independently of
depression symptoms. Also of note, the relationship between
anxiety and platelet function was found to be mediated by seroto-
nin but not epinephrine. Although serotonergic pathways have
been implicated in anxiety disorders,66 sympathetic activation is
also a hallmark of this clinical classification.67 This finding may in
part be a function of the co-morbid status of most patients with
classified with anxiety in the current study. Further research with
larger samples should address this issue.
Conclusions
The presence of anxiety symptoms is associated with higher plate-
let reactivity in stable CAD patients. This increase in platelet func-
tion is serotonin mediated and is independent of the effects of
depression. Anxiety may therefore be a better predictor of platelet
reactivity in CAD patients than depression.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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